| |
Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks - new study
|
| |
| |
https://www.clinicaltrials.gov/ct2/show/NCT02319031?term=NCT02319031&rank=1
Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)
Estimated Enrollment: 50
Study Start Date: February 2015
Estimated Study Completion Date: January 2016
This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2014 by Bristol-Myers Squibb
Sponsor:
Bristol-Myers Squibb
|
|
| |
| |
|
|
|
